1. Гарин А.М. Рак толстой кишки. М., 1998.
2. Myers MH, Gloeckler LA. Cancer patients survival rates. CA 1989; 39: 21.
3. Wingo PA, Tong T, Bolden S. Cancer statistics. CA 1995; 45: 8–30.
4. Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet 2005; 365: 153–65.
5. Grothey А, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14.
6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241–50.
7. De Jong JS, van Diest PJ et al. Expression of growth factors, growth-inhibiting factors and their receptors in invasive breast cancer: correlation with proliferation and angiogenesis. J Pathol 1998; 184: 53–7.
8. Weiner LM. Fully Human Therapeutic Monoclonal Antibodies. Immunother 2006; 29 (1): 1–9.
9. Jen J, Powell SM, Papadopoulos N et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 5523–6.
10. Van Engeland M, Roemen GM, Brink M et al. Kras mutations and RASSF1 a promoter methylation in colorectal cancer. Oncogene 2002; 21 (23): 3792–5.
11. Douillard JY, Siena S, Cassidy J. Randomized, phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer 2009; 7 (3 suppl): 10LBA.
12. Peeters M, Price T, Hotko Y et al. Randomized, phase 3 study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer 2009; 7 (3 suppl): 14LBA.
13. Peeters M, Van Cutsem E, Siena S et al. A Phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer. Proc Am Assoc Cancer Res 2006; 47: A CP–1, abstr.
14. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–34.
15. Amado RG, Wolf M, Freeman D et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur J Cancer Suppl 2007; 5: 8.
16. Elez 2008, Bosch 2008, Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–12.
17. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235–46.
18. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–12.
19. Gullick WJ, Hughes CM, Mellon K et al. Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol 1991; 164: 285–9.
20. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 (suppl 4): S9–S15.
21. Weiner LM et al. Panitumumab pharmacokinetics. Open-label, dose-finding study in advanced solid tumors. Proc Am Soc Clin Oncol 2005; 23: Abstr 3059.
22. Mitchell EP, Rose L, Ramirez M, Jacobs M. Dematological Toxicities with Panitumumab for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) from Three Clinical Studies. Annual Meeting Proceedings. Gastrointest Cancers Symp 2007; abstract 449.
23. Van Cutsem E et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658–64.
24. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nursing 2008; 12 (2): 283–90.
25. Pilon M, Mailhot M, Comtois A et al. Evaluation of a protocol algorithm for the treatment of epidermal growth factor receptor inhibitors-induced dermatological side effects (EPIDERM Study). ASCO 2008, abstr. 20755.
26. Ocvirk J, Rebersek M. Managing cutaneous side effects with K1 vitamine creme reduces cutaneous toxicities induced by cetuximab. ASCO 2008, abstr. 20750.
27. Lacouture ME, Mitchell EP, Piperdi B et al. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer/ published online ahead of print at www.jco.org on February 8, 2010.
28. Elez E, Macarulla T, Tabernero J. Handling side-effects of targeted therapies: safety of targeted therapies in solid timours. Ann Oncol 2008; Suppl 7: 146–52.
29. Bosch J, Abella L, Viudez A et al. Clinical impact on time to progression (TTP) of acneiform skin lesions in cetuximab-based regimens in colorectal cancer. ASCO 2008, abstr. 15096.
30. O’Callaghan CJ, Tu D, Karapetis CS et al. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17. ASCO 2008, abstr 4130.
31. Humblet Y, Peeters M, Siena S et al. Association of Skin Toxicity (ST) Severity With Clinical Outcomes and Health-Related Quality of Life (HRQoL) With Panitumumab (Pmab). J Clin Oncol 2007, ASCO 2007; 25 (18S): abstr. 4038.
32. Berlin J, Van Cutsem E, Peeters M. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. J Clin Oncol 2007, ASCO 2007; 25 (18S): abstr. 4134.
33. Douillard JY, Cassidy J, Jassem J et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). ASCO 2010; 28 (15S, part 1): p267s.
34. Berlin J, Van Cutsem E, Peeters M. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. Poster presented at ASCO; Feb. 22–24, Orlando,  Fl, 2007.
35. US FDA label, www.fda.gov.

Е.В.Артамонова

Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва